These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 23546446)

  • 1. Dyslipidaemia: Failure to THRIVE: the end for niacin?
    Wierzbicki AS
    Nat Rev Cardiol; 2013 May; 10(5):246-7. PubMed ID: 23546446
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin With Laropiprant on Health and Healthcare Costs.
    Kent S; Haynes R; Hopewell JC; Parish S; Gray A; Landray MJ; Collins R; Armitage J; Mihaylova B;
    Circ Cardiovasc Qual Outcomes; 2016 Jul; 9(4):348-54. PubMed ID: 27407053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dyslipidaemia: cardiovascular prevention--end of the road for niacin?
    Tuteja S; Rader DJ
    Nat Rev Endocrinol; 2014 Nov; 10(11):646-7. PubMed ID: 25178730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nicotinic acid plus laropiprant suspended for dyslipidaemia.
    Mayor S
    Lancet Diabetes Endocrinol; 2013 Aug; 1 Suppl 1():s6. PubMed ID: 24622598
    [No Abstract]   [Full Text] [Related]  

  • 5. Targeting multiple dyslipidemias with fixed combinations--focus on extended release niacin and simvastatin.
    Pandian A; Arora A; Sperling LS; Khan BV
    Vasc Health Risk Manag; 2008; 4(5):1001-9. PubMed ID: 19183748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia.
    Parhofer KG
    Vasc Health Risk Manag; 2009; 5():901-8. PubMed ID: 20016845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Multimodal therapy of dyslipidemia].
    Stahn A; Hanefeld M
    Clin Res Cardiol Suppl; 2011 May; 6():10-6. PubMed ID: 22528173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained hypophosphatemic effect of once-daily niacin/laropiprant in dyslipidemic CKD stage 3 patients.
    Ix JH; Ganjoo P; Tipping D; Tershakovec AM; Bostom AG
    Am J Kidney Dis; 2011 Jun; 57(6):963-5. PubMed ID: 21496982
    [No Abstract]   [Full Text] [Related]  

  • 9. Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control.
    Bays HE; Brinton EA; Triscari J; Chen E; Maccubbin D; MacLean AA; Gibson KL; Ruck RA; Johnson-Levonas AO; O'Neill EA; Mitchel YB
    Vasc Health Risk Manag; 2015; 11():165-72. PubMed ID: 25750540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin.
    Robinson JG
    Vasc Health Risk Manag; 2009; 5(1):31-43. PubMed ID: 19436666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Niacin, an old drug with new perspectives for the management of dyslipidaemia.
    Benhalima K; Muls E
    Acta Clin Belg; 2010; 65(1):23-8. PubMed ID: 20373594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Niacin extended-release/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapy.
    Toth PP; Thakker KM; Jiang P; Padley RJ
    Vasc Health Risk Manag; 2012; 8():39-44. PubMed ID: 22323895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended-release niacin (nicotinic acid)/laropiprant.
    Perry CM
    Drugs; 2009 Aug; 69(12):1665-79. PubMed ID: 19678716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Niacin extended release (ER)/simvastatin (Simcor®): a guide to its use in lipid regulation.
    Lyseng-Williamson KA
    Drugs R D; 2010; 10(4):253-60. PubMed ID: 21171671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic Variants Associated With Plasma Lipids Are Associated With the Lipid Response to Niacin.
    Tuteja S; Qu L; Vujkovic M; Dunbar RL; Chen J; DerOhannessian S; Rader DJ
    J Am Heart Assoc; 2018 Oct; 7(19):e03488. PubMed ID: 30371334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Managing the dyslipidemia of metabolic syndrome: beyond statin therapy.
    Jialal I; Smith G
    Metab Syndr Relat Disord; 2012 Jun; 10(3):159-60. PubMed ID: 22568574
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of Extended-Release Niacin on Quartile Lp-PLA
    Lyubarova R; Albers JJ; Marcovina SM; Yao Y; McBride R; Topliceanu A; Anderson T; Fleg JL; Desvigne-Nickens P; Kashyap ML; McGovern ME; Boden WE
    J Cardiovasc Pharmacol Ther; 2019 Nov; 24(6):534-541. PubMed ID: 31131629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination treatment with atorvastatin plus niacin provides effective control of complex dyslipidemias: a literature review.
    McKenney JM
    Postgrad Med; 2012 Jan; 124(1):7-20. PubMed ID: 22314110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remarkable quantitative and qualitative differences in HDL after niacin or fenofibrate therapy in type 2 diabetic patients.
    Masana L; Cabré A; Heras M; Amigó N; Correig X; Martínez-Hervás S; Real JT; Ascaso JF; Quesada H; Julve J; Palomer X; Vázquez-Carrera M; Girona J; Plana N; Blanco-Vaca F
    Atherosclerosis; 2015 Feb; 238(2):213-9. PubMed ID: 25528430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Nicotinic acid and the derivative].
    Ogaki S; Matsushima T
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():637-41. PubMed ID: 11347146
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.